Resistance mutation info of drug

Drug General Information
Drug ID D05ARP
Drug Name Ganciclovir Drug Info
Synonyms Citovirax; Cymevan; Cymeven; Cymevene; Cytovene; Ganciclovirum; Gancyclovir; HHEMG; Hydroxyacyclovir; Virgan; Vitrasert; Zirgan; GANCICLOVIR SODIUM; Ganciclovirum [Latin]; BW 759; BW 759U; Biolf 62; G 2536; GA2; IN1478; MB3795; BIOLF-62; BW-759U; BW-795; BW-B 759U; Cymevene (TN); Cytovene (TN); Cytovene-IV; DRG-0018; GCV & 1110U81; GCV & MSL; RS-21592; ST-605; Vitrasert (TN); Ganciclovir & C34-dgA immunotoxin; Ganciclovir & D5-dgA immunotoxin; Ganciclovir (JAN/USP/INN); Ganciclovir [USAN:INN:BAN:JAN]; Guanine, 9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-and MSL, neutralizing monoclonal antibody; 2'-NDG; 2'-Nor-2'-deoxyguanosine; 2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol; 2-Amino-1,9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-6-H-purin-6-one; 2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol; 2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-3H-purin-6-one; 2-amino-9-(2-hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone; 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-1,9-dihydro-6H-purin-6-one; 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one; 9-((1,3-Dihydroxy-2-propoxy)methyl)guanine; 9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine; 9-(1,3-DIHYDROXY-PROPOXYMETHANE)GUANINE; 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine; GCV
Drug Type Small molecular drug
Therapeutic Class Antiviral Agents
Company Bausch & Lomb Pharmaceuticals, Inc.
Structure D05ARP
Drug Resistance Mutations
Target Name HCMV DNA polymerase catalytic subunit (UL54) Target Info
Gene Name UL54
Uniprot ID DPOL_HCMVA
Species Human cytomegalovirus
Reference Sequence MFFNPYLSGGVTGGAVAGGRRQRSQPGSAQGSGKRPPQKQFLQIVPRGVMFDGQTGLIKH
KTGRLPLMFYREIKHLLSHDMVWPCPWRETLVGRVVGPIRFHTYDQTDAVLFFDSPENVS
PRYRQHLVPSGNVLRFFGATEHGYSICVNVFGQRSYFYCEYSDTDRLREVIASVGELVPE
PRTPYAVSVTPATKTSIYGYGTRPVPDLQCVSISNWTMARKIGEYLLEQGFPVYEVRVDP
LTRLVIDRRITTFGWCSVNRYDWRQQGRASTCDIEVDCDVSDLVAVPDDSSWPRYRCLSF
DIECMSGEGGFPCAEKSDDIVIQISCVCYETGGNTAVDQGIPNGNDGRGCTSEGVIFGHS
GLHLFTIGTCGQVGPDVDVYEFPSEYELLLGFMLFFQRYAPAFVTGYNINSFDLKYILTR
LEYLYKVDSQRFCKLPTAQGGRFFLHSPAVGFKRQYAAAFPSASHNNPASTAATKVYIAG
SVVIDMYPVCMAKTNSPNYKLNTMAELYLRQRKDDLSYKDIPRCFVANAEGRAQVGRYCL
QDAVLVRDLFNTINFHYEAGAIARLAKIPLRRVIFDGQQIRIYTSLLDECACRDFILPNH
YSKGTTVPETNSVAVSPNAAIISTAAVPGDAGSVAAMFQMSPPLQSAPSSQDGVSPGSGS
NSSSSVGVFSVGSGSSGGVGVSNDNHGAGGTAAVSYQGATVFEPEVGYYNDPVAVFDFAS
LYPSIIMAHNLCYSTLLVPGGEYPVDPADVYSVTLENGVTHRFVRASVRVSVLSELLNKW
VSQRRAVRECMRECQDPVRRMLLDKEQMALKVTCNAFYGFTGVVNGMMPCLPIAASITRI
GRDMLERTARFIKDNFSEPCFLHNFFNQEDYVVGTREGDSEESSALPEGLETSSGGSNER
RVEARVIYGDTDSVFVRFRGLTPQALVARGPSLAHYVTACLFVEPVKLEFEKVFVSLMMI
CKKRYIGKVEGASGLSMKGVDLVRKTACEFVKGVTRDVLSLLFEDREVSEAAVRLSRLSL
DEVKKYGVPRGFWRILRRLVQARDDLYLHRVRVEDLVLSSVLSKDISLYRQSNLPHIAVI
KRLAARSEELPSVGDRVFYVLTAPGVRTAPQGSSDNGDSVTAGVVSRSDAIDGTDDDADG
GGVEESNRRGGEPAKKRARKPPSAVCNYEVAEDPSYVREHGVPIHADKYFEQVLKAVTNV
LSPVFPGGETARKDKFLHMVLPRRLHLEPAFLPYSVKAHECC [Human cytomegalo
virus]
Targeted Disease Bacterial infection
Drug Resistance Mutations
Mutation info Missense: L802M [1559221]
Mutation Prevalence 3.3% of patients
Target Name HCMV Serine/threonine protein kinase (UL97) Target Info
Gene Name UL97
Uniprot ID UL97_HCMVA
Species Human cytomegalovirus
Reference Sequence MSSALRSRARSASLGTTTQGWDPPPLRRPSRARRRQWMREAAQAAAQAAVQAAQAAAAQV
AQAHVDENEVVDLMADEAGGGVTTLTTLSSVSTTTVLGHATFSACVRSDVMRDGEKEDAA
SDKENLRRPVVPSTSSRGSAASGDGYHGLRCRETSAMWSFEYDRDGDVTSVRRALFTGGS
DPSDSVSGVRGGRKRPLRPPLVSLARTPLCRRRVGGVDAVLEENDVELRAESQDSAVASG
PGRIPQPLSGSSGEESATAVEADSTSHDDVHCTCSNDQIITTSIRGLTCDPRMFLRLTHP
ELCELSISYLLVYVPKEDDFCHKICYAVDMSDESYRLGQGSFGEVWPLDRYRVVKVARKH
SETVLTVWMSGLIRTRAAGEQQQPPSLVGTGVHRGLLTATGCCLLHNVTVHRRFHTDMFH
HDQWKLACIDSYRRAFCTLADAIKFLNHQCRVCHFDITPMNVLIDVNPHNPSEIVRAALC
DYSLSEPYPDYNERCVAVFQETGTARRIPNCSHRLRECYHPAFRPMPLQKLLICDPHARF
PVAGLRRYCMSELSALGNVLGFCLMRLLDRRGLDEVRMGTEALLFKHAGAACRALENGKL
THCSDACLLILAAQMSYGACLLGEHGAALVSHTLRFVEAKMSSCRVRAFRRFYHECSQTM
LHEYVRKNVERLLATSDGLYLYNAFRRTTSIICEEDLDGDCRQLFPE [Human cytom
egalovirus]
Targeted Disease Bacterial infection
Drug Resistance Mutations
Mutation info Missense: M460V [556138], [1559221]
Mutation Prevalence 3.3% of patients
Mutation info Missense: D605E [1559224]
Mutation Prevalence 30 out of 70
Mutation info Missense: C518Y [1559224]
Mutation info Missense: C607F [1559224]
Mutation info Missense: L595W [1559224]
Mutation info Missense: A594V [556138]
Mutation Prevalence 26.43% of the specimens
Mutation info Missense: C592G [556138]
Mutation Prevalence 10.34% of the specimens
Mutation info Missense: C603W [556138]
Mutation Prevalence 6.89% of the specimens
Mutation info Missense: E596G [556138]
Mutation Prevalence 1.14% of the specimens
Mutation info Missense: H520Q [556138]
Mutation Prevalence 18.39% of the specimens
Mutation info Missense: L595S [556138]
Mutation Prevalence 2.29% of the specimens
Mutation info Missense: M460I [556138]
Mutation Prevalence 9.19% of the specimens
Mutation info Deletion: A594 [556138]
References
Ref 536361Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20.
Ref 556138Assessment of the Human Cytomegalovirus UL97 Gene for Identification of Resistance to Ganciclovir in Iranian Immunosuppressed Patients. Jundishapur J Microbiol. 2016 May 29;9(5):e31733. doi: 10.5812/jjm.31733. eCollection 2016 May.
Ref 1559224A new mutation in the human cytomegalovirus UL97 gene may confer ganciclovir resistance in Chinese kidney transplant recipients.Arch Virol.2013 Jan;158(1):247-50.
Ref 1559221[Investigation of ganciclovir resistance in CMV UL54 and UL97 gene regions in immunocompromised patients receiving gancyclovir treatment].Mikrobiyol Bul.2015 Jul;49(3):393-402.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.